QIAGEN N.V.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $QGEN in the last 30 days.
See all $QGEN insider activity →Qiagen's QIAstat-Dx BCID GN Plus AMR Panel, cleared by the FDA, detects 13 gram-negative bacteria and 18 antibiotic resistance markers in about an hour. The test complements the previously cleared gram-positive and fungal panel, offering rapid bloodstream infection identification. Qiagen aims to support timely treatment decisions and address antibiotic resistance, with the QIAstat-Dx system available in over 100 countries.
QIAGEN received FDA clearance for a new QIAstat-Dx panel that detects 13 gram-negative bacteria and 18 antibiotic resistance markers in about an hour. Combined with its existing panel, the system covers 33 pathogens and 28 resistance markers. Bloodstream infections, which can lead to sepsis, affect 1.7 million U.S. adults annually, causing 350,000 deaths. The QIAstat-Dx system is used in over 100 countries.
QIAGEN N.V. reported that BlackRock, Inc. holds 11.42% capital interest and 12.83% voting rights in the company, according to a Dutch AFM disclosure. The notification was dated September 18, 2026.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning QGEN (QIAGEN N.V.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent QGEN coverage spans regulation, financial news and market movers.
The clearance adds a new gram‑negative bloodstream infection test, likely boosting Qiagen's US sales pipeline.
First FDA clearance expands QIAGEN's infectious disease testing menu.
QIAGEN N.V. reported that BlackRock, Inc. holds 11.42% capital interest and 12.83% voting rights in the company, according to a Dutch AFM disclosure. The notification was dated September 18, 2026.
M&A speculation supports price.
Potential acquisition interest could drive further upside if bids materialize.
AlphAI scores every news story that mentions QGEN with an AI model for sentiment and relevance, and aggregates insider trades from QIAGEN N.V.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Qiagen's QIAstat-Dx BCID GN Plus AMR Panel, cleared by the FDA, detects 13 gram-negative bacteria and 18 antibiotic resistance markers in about an hour. The test complements the previously cleared gram-positive and fungal panel, offering rapid bloodstream infection identification. Qiagen aims to support timely treatment decisions and address antibiotic resistance, with the QIAstat-Dx system available in over 100 countries.
2 min readQIAGEN received FDA clearance for a new QIAstat-Dx panel that detects 13 gram-negative bacteria and 18 antibiotic resistance markers in about an hour. Combined with its existing panel, the system covers 33 pathogens and 28 resistance markers. Bloodstream infections, which can lead to sepsis, affect 1.7 million U.S. adults annually, causing 350,000 deaths. The QIAstat-Dx system is used in over 100 countries.
1 min readQIAGEN N.V. reported that BlackRock, Inc. holds 11.42% capital interest and 12.83% voting rights in the company, according to a Dutch AFM disclosure. The notification was dated September 18, 2026.
1 min readStocks are poised to recover after the Fed's rate hike, with tech and AI-related sectors leading the rebound. Key movers include Generac (GNRC +29% after an Amazon deal), Fluence Energy (FLNC -21% on lowered guidance), and Ciena (CIEN +3% on positive analyst sentiment). Bond yields dropped, and oil prices fell, easing inflation concerns. The Fed's dot plot suggests one more hike this year, while markets weigh future rate expectations.
3 min readQiagen (QGEN) shares rose 4% after a report suggested private equity firms like TPG, Bain Capital, KKR, EQT, and Advent may be considering offers. No official statements have been made by the companies involved.
1 min readQIAGEN (QGEN) launched QIAsymphony Connect, an automated platform for clinical nucleic acid extraction. The company reported Q2 net sales of $535M, beating guidance, with growth pillars like Sample technologies and QIAcuity driving performance. However, some segments faced challenges, and the full-year outlook was reaffirmed. The stock trades at a forward P/E of 13.16, with mixed institutional interest.
3 min readQIAGEN reported that BlackRock holds 11.51% capital interest and 12.91% voting rights in the company, as disclosed by the Dutch AFM. The holdings are indirect and include potential stakes via affiliates. This is a regulatory disclosure of a large holder's stake in QIAGEN.
1 min readBerenberg maintains a neutral rating on Qiagen N.V. The company's stock has seen a 5-day change of 42.13 USD, a 1st Jan change of -0.87%, and a year-to-date change of -3.94%. Qiagen also announced the resignation of Thierry Bernard from its Managing Board, effective September 1, 2026.
1 min readQiagen (QGEN) disclosed a managers' transaction under EU Market Abuse Regulation, awarding CEO Jonathan M. Pratt over 170,000 performance share units. The awards depend on company goals and shareholder return, aligning executive compensation with long-term performance. The transaction occurred on September 1, 2026, as part of Qiagen's incentive programs.
1 min readUBS maintained a Neutral rating on Qiagen (QGEN) but lowered its price target to $47.00 from $52.00. GuruFocus values QGEN at $49.37, suggesting it is 14.0% undervalued. The company's P/E (TTM) is 21.47x, below its 5-year median. Analysts have mixed views on QGEN, with some seeing potential for value appreciation.
2 min read
